title: A 10-week randomised, double-blind, parallel-group, placebo-controlled phase 2 study to investigate the extent of symptom relief and the safety and tolerability of SMP-986 (20 mg, 40 mg, 80 mg and 120 mg) administered once daily for 8 weeks to patients with overactive bladder syndrome

acronym: SMP-986 phase 2 proof of concept in patients with OABS

lead_sponsor: Dainippon Sumitomo Pharma Europe Ltd.


title: A single-blind, placebo-controlled, multicentre study evaluating continued long-term treatment with satavaptan (SR121463B) in patients with ascites due to liver cirrhosis who have previously been treated in studies LTS5634 or LTS5635.

source: euctr

lead_sponsor: sanofi-aventis recherche et développement

study_type: Interventional

status: Completed

lead_sponsor_type: industriel

status_simplified: Completed


title: A Phase III, Multicenter, Randomized, Controlled, Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Ophthalmic Cationic Emulsion versus Vehicle in Patients with Moderate to Severe Dry Eye Syndrome

acronym: SICCANOVE

lead_sponsor: Novagali Pharma S.A.


title: A multi-centre, multinational, open-label single-dose acute hemodynamic study followed by a multi-centre, multinational, randomized, double-blind, parallel-group, placebo controlled study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy (proof-of-concept) of NS-304 in the treatment of pulmonary arterial hypertension in subjects aged 18 years and over

lead_sponsor: Nippon Shinyaku Co., LTD


title: A Phase III, Multicentre, Randomised, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable CUV1647 Implants in Patients with Erythropoietic Protoporphyria (EPP)

acronym: Multicentre Phase III EPP Study

lead_sponsor: Clinuvel Pharmaceuticals Limited


title: A Study of INT-747 (6-ECDCA) in Combination with Ursodeoxycholic Acid (URSO®, UDCA) in Patients with Primary Biliary Cirrhosis

lead_sponsor: Intercept Pharmaceuticals


title: Open-Label Extension for Alzheimer’s Disease Patients Who Complete One of Two Semagacestat Phase 3 Double-Blind Studies (H6L-MC-LFAN or H6L-MC-LFBC)

lead_sponsor: Eli Lilly and Company


title: A PHASE 2, RANDOMIZED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND ANTI-CYTOMEGALOVIRUS (CMV) ACTIVITY OF MARIBAVIR VERSUS VALGANCICLOVIR FOR TREATMENT OF CMV INFECTIONS IN TRANSPLANT RECIPIENTS WHO DO NOT HAVE CMV ORGAN DISEASE

lead_sponsor: VIROPHARMA INCORPORATED

status: Ongoing

status_simplified: Ongoing


title: A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failure in patients aged ≥ 65 and patients aged ≥18 with at least one additional risk factor who are infected with SARS-CoV-2. (the MiR-AGE study).

lead_sponsor: ABIVAX

status: Prematurely Ended

status_simplified: Unknown


title: A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma

acronym: Phase III trial of pembrolizumab or brentuximab vedotin in Hodgkin lymphoma

lead_sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.


title: A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patients with Alagille Syndrome (ASSERT)

lead_sponsor: Albireo AB


title: A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL,  CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF  ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS DOCETAXEL MONOTHERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER PREVIOUSLY TREATED WITH AN ANTI-PD-L1/PD-1 ANTIBODY AND PLATINUM-CONTAINING CHEMOTHERAPY

lead_sponsor: F. Hoffman-La Roche Ltd.


title: A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Gemcitabine Plus Nab-paclitaxel as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer

acronym: Not available

lead_sponsor: FibroGen, Inc.


title: A one-year placebo-controlled phase III trial evaluating the efficacy and safety of the house dust mite (HDM) SLIT-tablet in children (5-11 years of age) with HDM allergic rhinitis/rhinoconjunctivitis with or without asthma

lead_sponsor: ALK-Abelló A/S


title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, with an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults with Hypoparathyroidism

lead_sponsor: Ascendis Pharma Bone Diseases A/S


title:
A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia

 Étude de Phase 3b, multicentrique, en ouvert, à un bras, évaluant l’acalabrutinib (ACP-196) chez des patients présentant une leucémie lymphoïde chronique

lead_sponsor: AstraZeneca AB


title:
A DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 24 WEEKS TREATMENT WITH REN001 IN PATIENTS WITH PRIMARY MITOCHONDRIAL MYOPATHY (PMM)

 ÉTUDE EN DOUBLE AVEUGLE, CONTRÔLÉE CONTRE PLACEBO, VISANT À ÉVALUER L’EFFICACITÉ ET LA TOLERANCE D’UN TRAITEMENT DE 24 SEMAINES PAR REN001 CHEZ DES PATIENTS ATTEINTS DE MYOPATHIE MITOCHONDRIALE PRIMAIRE (MMP)

acronym: Phase 2b Safety and Efficacy Study of REN001 in Mitochondrial Myopathy

lead_sponsor: Reneo Pharma Ltd.


title: A Randomized, Double-blind, Multi-center Phase III Study of Brivanib plus Best Supportive Care (BSC) versus Placebo plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) who have Failed or are Intolerant to Sorafenib: The BRISK Study

acronym: BRISK study

lead_sponsor: Bristol Myers Squibb International Corporation


title: A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohorts, Dose Range Finding Study to Evaluate the Safety, Tolerability and Clinical Effect of Escalating Doses of Laquinimod in Active Moderate to Severe Crohn’s Disease

lead_sponsor: Teva Pharmaceutical Industries Ltd.


title: CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve-Month Safety and Efficacy Study Evaluating Dimebon in Patients with Mild-to-Moderate Alzheimer’s Disease on Donepezil

acronym: CONCERT

lead_sponsor: Medivation, Inc.


title: Initiation of agomelatine after antidepressant treatment by SSRI or SNRI in outpatients suffering Major Depressive Disorder. A 3-week, randomised, double then single-blind, controlled, parallel groups, international, multicentre safety study with a 5-week open extension period.

lead_sponsor: Institut de Recherches Internationales Servier


title: Phase III Trial Evaluating the Role of Adjuvant Pegylated Liposomal Doxorubicin (PLD, Caelyx®, Doxil®) for Women (age 66 years or older) with Endocrine Nonresponsive Breast Cancer Who Are NOT Suitable for Being Offered a “Standard Chemotherapy Regimen”

acronym: Chemotherapy Adjuvant Study for women at advanced Age (CASA)

lead_sponsor: International Breast Cancer Study Group (IBCSG)


title: A Phase II, Double-Blind, Placebo Controlled, Multi-Centre, Randomised Study of AZD0530 in Patients with Advanced Ovarian Cancer Sensitive to Platinum-Based Chemotherapy


title: A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Phase III, Efficacy and Safety Study of 3 Fixed Dose Groups of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy


title: An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis


title: A Phase II, Open-label, 1:1 Randomized, Controlled Trial Exploring the Efficacy of EMD 1201081 in Combination with Cetuximab in Second-Line Cetuximab-Naïve Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)

acronym: EMD 1201081 in Cetuximab-Naïve Subjects with R/M SCCHN

lead_sponsor: Merck KGaA


title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of CEP-33457 in Patients With Systemic Lupus Erythematosus

acronym: Celestial 47

lead_sponsor: Cephalon, Inc.


title: An open-label trial with TMC125 as part of an ART including TMC114/rtv and an investigator-selected OBR in HIV-1 infected subjects who participated in a DUET trial (TMC125-C206 or TMC125-C216).

lead_sponsor: Tibotec Pharmaceuticals Limited


title: A Phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in combination with a background regimen containing 2 nucleoside/nucleotide reverse transcriptase inhibitors in antiretroviral-naïve HIV-1 infected subjects

acronym: Thrive


title: A Phase IIa, Double-blind, Randomised, Parallel-group, Multi-centre Study to Evaluate the Analgesic Efficacy of 28 Days Oral Administration of AZD2423 Compared to Placebo in Patients with Posttraumatic Neuralgia


title: A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE EFFICACY AND SAFETY OF BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY REGIMENS IN SUBJECTS WITH PREVIOUSLY TREATED METASTATIC BREAST CANCER

lead_sponsor: Genentech Inc.


title: A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study, to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sulphonylurea Therapy

acronym: CANTATA-MSU Trial

lead_sponsor: Janssen-Cilag International NV


title: A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX-4 plus cetuximab versus UFOX plus cetuximab as first-line therapy in subjects with metastatic colorectal cancer

acronym: FUTURE


title: A Phase 1b/ 2 Trial of AMG 479 or AMG 102 in Combination with Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer

lead_sponsor: Amgen Inc


title: A Phase 1b/2 Study to Assess the Safety and Efficacy of AMG 102 in Combination with Mitoxantrone and Prednisone in Subjects with Previously Treated Castrate Resistant Prostate Cancer


title: The Safety and Efficacy of AL-8309B Ophthalmic Solution for the Treatment of Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

acronym: Geographic Atrophy Treatment Evaluation (GATE)

lead_sponsor: Alcon Research, Ltd


title: A Randomized, Double Blind, Multi-Center, Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Cisplatin & Capecitabine (CX) in Combination with AMG 386 or Placebo in Subjects with Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma

lead_sponsor: Amgen Inc.


title: A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

lead_sponsor: Janssen Cilag international NV


title: A Phase III Open-Label, Single-Group Extension Study to Obtain Long-Term Safety and Tolerability Data of Idebenone in the Treatment of Friedreich's Ataxia Patients

acronym: MICONOS EXTENSION

lead_sponsor: Santhera Pharmaceuticals (Switzerland) Ltd


title: The Impact of LY2189265 versus Metformin on Glycemic Control in Early Type 2 Diabetes Mellitus (AWARD-3: Assessment of Weekly AdministRation of LY2189265 in Diabetes-3)

acronym: GBDC

lead_sponsor: Eli Lilly & Company - Indianapolis


title:
A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-Controlled
 Study to Evaluate the Efficacy and Safety of Relaxin in Subjects With Acute Heart Failure.

acronym: RELAX-AHF

lead_sponsor: Corthera, Inc.


title: A randomised, double-blind, parallel group, equivalence, multicentre phase III trial to compare the efficacy, safety and pharmacokinetics of HD201 to Herceptin® in patients with HER2+ early breast cancer

acronym: Troika

lead_sponsor: Prestige BioPharma Pte Ltd


title: A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-224)

acronym: Phase II MK-3475 in subjects with  previously treated Hepatocellular Carcinoma

lead_sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.


title: A randomized, double blind, parallel-group, placebo controlled study to evaluate the efficacy and safety of IBP-9414 in premature infants 500-1500g birth weight in the prevention of necrotizing enterocolitis – The Connection study

acronym: The Connection study

lead_sponsor: Infant Bacterial Therapeutics AB (IBT)


title:
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment

  Étude randomisée, en double aveugle et contrôlée contre placebo, visant à évaluer la sécurité d’emploi et l’efficacité du Crinécerfont (NBI-74788) chez des sujets enfants atteints d'une forme classique d’hyperplasie congénitale des surrénales, suivi d’un traitement en ouvert.

lead_sponsor: Neurocrine Biosciences, Inc.


title:
An open-label, multicenter, extension study to evaluate the long-term safety and tolerability of LOU064 in eligible subjects with CSU who have participated in preceding studies with LOU064

 Etude d’extension, multicentrique, en ouvert, évaluant la tolérance et la sécurité d’emploi à long terme de LOU064 chez les patients éligibles souffrant d’urticaire chronique spontanée (UCS) et ayant participé à des études précédentes portant sur LOU064

lead_sponsor: Novartis Pharma AG


title:
Prospective, randomized, controlled, double-blind, multicentre, multinational study on the safety and efficacy of 6% Hydroxyethyl starch (HES) solution versus an electrolyte solution in patients undergoing elective abdominal surgery

 Étude prospective, randomisée, contrôlée, en double aveugle, multicentrique, internationale, visant à évaluer la sécurité et l’efficacité d’une solution d’hydroxyéthylamidon (HEA) à 6 % par comparaison avec une solution électrolytique chez des patients bénéficiant d’une chirurgie abdominale non urgente

acronym: PHOENICS

lead_sponsor: B. Braun Melsungen AG


title:
A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel Group Study to Evaluate the Efficacy and Safety of Opicapone, as Add on to Stable Levodopa (L-DOPA) Plus a Dopa Decarboxylase Inhibitor (DDCI) Therapy in Early Idiopathic Parkinson’s Disease Patients, with an Open-Label Extension
 The EPSILON Study: Early Parkinson wIth L-DOPA/DDCI and Opicapone

acronym: EPSILON

lead_sponsor: BIAL – Portela & Cª, S.A.


title: A Phase 1/2 trial on the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy of DYN101 in patients ≥ 16 years of age with centronuclear myopathies caused by mutations in DNM2 or MTM1

acronym: Research Using an Investigational Treatment for CNM (Unite-CNM)

lead_sponsor: Dynacure SAS


title:
AIPAC (Active Immunotherapy PAClitaxel): A multicentre, Phase IIb, randomised, double blind, placebo-controlled study in hormone receptor-positive metastatic breast carcinoma patients receiving IMP321 (LAG-3Ig fusion protein) or placebo as adjunctive to a standard chemotherapy treatment regimen of paclitaxel.

 AIPAC (Active Immunotherapy PAClitaxel) : étude multicentrique, randomisée, à double insu, contrôlée par placebo de phase IIb menée chez des patientes souffrant d'un carcinome mammaire métastatique à récepteurs hormonaux positifs recevant IMP321 (protéine de fusion LAG-3Ig) ou un placebo en complément d'un régime chimiothérapeutique standard par paclitaxel.

acronym:
AIPAC

 AIPAC

lead_sponsor: Immutep S.A.S.


title:
An open-label, non-randomized extension study to evaluate the long term safety, tolerability, efficacy and pharmacokinetics of CDZ173 (leniolisib) in patients with APDS/PASLI (Activated phosphoinositide 3-kinase delta syndrome/p110δ- activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency)

 Etude d’extension, en ouvert, non randomisée, évaluant la sécurité d'emploi, la tolérance et l’efficacité à long terme ainsi que la pharmacocinétique de CDZ173 (leniolisib) chez des patients atteints d’APDS/PASLI (syndrome de PI3K-delta activée/déficit immunitaire, lymphadénopathie et cellules T sénescentes dus à des mutations activatrices de p110-delta)

acronym: Extension to the study of safety and efficacy of CDZ173 in patients with APDS/PASLI

lead_sponsor: Novartis Pharma Services AG


title: A Global, Multicenter, Randomized, Placebo-Controlled Phase 3 Trial to Compare the Efficacy and Safety of Fruquintinib Plus Best Supportive Care to Placebo Plus Best Supportive Care in Patients with Refractory Metastatic Colorectal Cancer (FRESCO-2)

acronym: Refer to the protocol

lead_sponsor: Hutchison MediPharma Limited


title:
A Phase IIa study to evaluate the safety and efficacy of ABX464 50 mg once daily versus Placebo in subjects with Moderate to Severe Active Ulcerative Colitis who have failed or are intolerant to immunomodulators, Anti-TNFα, vedolizumab and/or corticosteroids.

 Etude de phase IIa comparant la tolérance et l’efficacité d’ABX464 administré à la dose quotidienne de 50 mg à un placebo chez des sujets présentant une rectocolite hémorragique active modérée à sévère résistants ou intolérants aux traitements immunomodulateurs, aux Anti-TNFα, au vedolizumab et/ou aux corticoïdes.

acronym:
Safety and efficacy study of ABX464 in patients with moderate to severe Active Ulcerative Colitis.

 Etude de tolérance et d’efficacité de l’ABX464 chez des patients atteints de colite ulcéreuse active

lead_sponsor: ABIVAX


title: ENGOT-EN1/FANDANGO: A randomized phase II trial of first-line combination chemotherapy with nintedanib / placebo for patients with advanced or recurrent endometrial cancer.

lead_sponsor: Nordic Society of Gynaecological Oncology (NSGO)


title:
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema with Normal C1-Inhibitor (C1-INH)

 Étude de phase III, multicentrique, randomisée, contrôlée contre placebo, en double aveugle, évaluant l’efficacité et la sécurité d’emploi du lanadélumab pour la prévention de crises aiguës d’angio-œdème non histaminique à C1 Inhibiteur normal (C1-INH)

lead_sponsor: Dyax Corporation, a Takeda company


title:
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
 Randomized, international and multicentric phase 3 study that evaluates and compares 2 treatment strategies in 3 therapeutic phases (induction, high-dose chemotherapy and radiotherapy) for patients with high-risk neuroblastoma.

 Etude internationale multicentrique de phase 3 randomisée qui évalue et compare 2 stratégies de traitement dans 3 phases thérapeutiques (induction, chimiothérapie à haute dose et radiothérapie) pour les patients atteints de neuroblastome de haut-risque.

lead_sponsor: Gustave Roussy

lead_sponsor_type: academique


title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis

lead_sponsor: Galderma S.A.


title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of ST-0529 in Subjects with Moderately to Severely Active Ulcerative Colitis

lead_sponsor: Sublimity Therapeutics (Hold Co) Ltd.


title:
A Compassionate Use Open-Label Study of Anti IL-5
 (Mepolizumab) Treatment in Subjects with Hypereosinophilic
 Syndrome

lead_sponsor: GlaxoSmithKline Resaearch and Development Ltd


title: A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second-Line Cervical Cancer

lead_sponsor: Agenus Inc.


title:
SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase 2 Study Comparing the Efficacy and Safety of Oral AZD9833 versus Fulvestrant in Women with Advanced ER-Positive HER2-Negative Breast Cancer

 SERENA-2 : Étude de phase 2 multicentrique, randomisée, ouverte, à groupes parallèles comparant l'efficacité et l'innocuité de l'AZD9833 administré par voie orale par rapport au fulvestrant chez des femmes atteintes de cancer du sein avancé ER positif et HER2 négatif

lead_sponsor: AstraZeneca AB


title: A Phase 3, randomized, double-blind, active controlled study to compare the efficacy and safety of ridinilazole (200 mg, bid) for 10 days with vancomycin (125 mg, qid) for 10 days in the treatment of Clostridium difficile infection (CDI).

lead_sponsor: Summit (Oxford) Limited


title:
A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection versus Intravenous Caspofungin Followed by Optional Oral Fluconazole Step-down in the Treatment of Subjects with Candidemia and/or Invasive Candidiasis (The ReSTORE Study)

 Étude de phase 3, multicentrique, randomisée, en double aveugle évaluant l'efficacité et la sécurité des injections de Rezafungine par rapport à la Caspofungine administrée en intraveineux avec un relai possible par Fluconazole par voie orale dans le traitement des patients atteints de candidémie et/ou de candidose invasive (étude ReSTORE)

lead_sponsor: Cidara Therapeutics Inc.


title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)

lead_sponsor: GB002, Inc.


title:
Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients with rare genetic disorders of obesity

 Essai thérapeutique de phase 2 portant sur la setmélanotide (RM-493) chez des patients atteints de maladies génétiques rares de l’obésité

acronym: Basket Study

lead_sponsor: Rhythm Pharmaceuticals, Inc.


title:
Long Term Extension Trial of setmelanotide (RM-493) for patients who have completed a trial of Setmelanotide for the treatment of obesity associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway.

 Essai d'extension à long terme portant sur la setmélanotide (RM-493) chez des patients ayant terminé un essai utilisant la setmélanotide dans le traitement de l'obésité liée à des défauts génétiques en amont du récepteur aux mélanocortines de type 4 (MC4R) dans la voie leptine-mélanocortine


title: A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine administered every two months from a Bictegravir/emtricitabine/tenofovir alafenamide Single Tablet Regimen in HIV-1 Infected Adults who are Virologically Suppressed

acronym: PH3b, CAB LA+RPV LA vs BIK, IM Every 2Months, Non-inferiority, Efficacy&Safety in Participants HIV-1

lead_sponsor: ViiV Healthcare UK Limited


title: A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo

acronym: Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)

lead_sponsor: Incyte Corporation


acronym: Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)


title: A PHASE IIIB, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL EFFICACY STUDY OF BALOXAVIR MARBOXIL FOR THE REDUCTION OF DIRECT TRANSMISSION OF INFLUENZA FROM OTHERWISE HEALTHY PATIENTS TO HOUSEHOLD CONTACTS

acronym: Centerstone

lead_sponsor: F. Hoffmann-La Roche Ltd


title:
A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation

 Étude de phase 3, internationale, en double aveugle, randomisée, contrôlée par placebo portant sur le MGL 3196 (resmétirom) chez des patients atteints d’une stéatohépatite non alcoolique (Non-Alcoholic Steatohepatitis, NASH) avec fibrose hépatique visant à faire disparaître la NASH et à diminuer la progression vers une cirrhose et/ou une décompensation hépatique

lead_sponsor: Madrigal Pharmaceuticals, Inc.


title: A double-blind, placebo controlled, multicentre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled Promixin® (colistimethate sodium) in the treatment of subjects with non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa (P. aeruginosa)

acronym: PROMIS II

lead_sponsor: Zambon S.p.A.


title: Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (≥60 years) with Relapsed/Refractory Acute Myeloid Leukemia (AML)

acronym: ARMADA 2000

lead_sponsor: Rafael Pharmaceuticals, Inc.


title: A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Pemphigus (Vulgaris or Foliaceus) (ADDRESS)

acronym: ADDRESS

lead_sponsor: argenx BV


title:
Phase IIb, Placebo-Controlled, Randomized, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB) Single Implantation in Tibial Fracture

 Étude de phase IIb, contrôlée par placebo, randomisée, en double aveugle, multicentrique, visant à évaluer l’efficacité et la sécurité d’emploi d’une implantation unique de cellules ostéoblastiques allogéniques (ALLOB®) dans la fracture du tibia

lead_sponsor: Bone Therapeutics S.A.


title: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis

lead_sponsor: Caelum Biosciences, Inc.


title: A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab- Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease

lead_sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.


title:
A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients with Epithelial Ovarian Cancer  Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy (OReO)

 Etude de Phase IIIb, multicentrique, randomisée, en double aveugle contre placebo, de l'Olaparib en traitement d'entretien chez des patientes atteintes de cancer épithélial de l'ovaire précédemment traité par iPARP et répondant à une nouvelle chimiothérapie à base de platine (OReO)

acronym: OReO


title: A phase IIb, prospective, multicentre, double-blind, triple-arm, randomized versus placebo trial, to assess the efficacy of a single injection of either 2 or 10 x 106 autologous adipose derived mesenchymal stromal cells (ASC) in the treatment of mild to moderate osteoarthritis (OA) of the knee, active and unresponsive to conservative therapy for at least 12 months.

acronym:
ADIPOA 2

 ADIPOA 2

lead_sponsor: CHU Montpellier


title:
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer

 Étude de Phase III randomisée en double aveugle évaluant l’efficacité et la sécurité d’emploi du capivasertib + paclitaxel versus placebo + paclitaxel dans le traitement de première ligne de patients présentant un cancer du sein triple négatif confirmé histologiquement, localement avancé (inopérable) ou métastatique


title:
A randomized, subject and investigator blinded, placebo controlled and multi-center platform study, to assess efficacy and safety of different investigational drugs in patients with moderate to severe hidradenitis suppurativa

 Etude multicentrique, randomisée, en double aveugle, contrôlée par placebo, conçue en plateforme, évaluant l’efficacité et la sécurité d’emploi de l’iscalimab (CFZ533) et de LYS006 chez des patients atteints d’hidradénite suppurée modérée à sévère

acronym: Efficacy and safety of different investigational drugs for the treatment of hidradenitis suppurativa

lead_sponsor: Novartis Pharma AG


title:
A 52-week, randomised, double-blind, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of GSK3511294 adjunctive therapy in adult and adolescent participants with severe uncontrolled asthma with an eosinophilic phenotype

 Étude multicentrique de 52 semaines, randomisée, en double aveugle, contrôlée par placebo, à groupes parallèles, de l’efficacité et de la sécurité d’emploi du traitement adjuvant par GSK3511294 chez des patients adultes et adolescents atteints d’asthme sévère non contrôlé avec un phénotype éosinophilique.

lead_sponsor: GlaxoSmithKline Research & Development Limited


title: A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants

acronym: Ph2 Platform Trial of Novel Regimens vs. SoC in NSCLC

lead_sponsor: GlaxoSmithKline Research and Development Ltd.


title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination with Acalabrutinib in Subjects with Relapsed/Refractory Diffuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic Leukemia

lead_sponsor: Kartos Therapeutics Inc.


title: A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2−) Breast Cancer Following Recurrence or Progression On or After Treatment with an Aromatase Inhibitor (CAPItello-291)

lead_sponsor: AstraZeneca AB


title:
A randomized, double blind, placebo-controlled, multi-center, parallel group study to evaluate the efficacy and safety of dupilumab in patients with prurigo nodularis who are inadequately controlled on topical prescription therapies or when those therapies are not advisable

 Étude randomisée, en double aveugle, contrôlée par placebo, multicentrique, en groupes parallèles, visant à évaluer l’efficacité et la sécurité d’emploi du dupilumab chez des patients atteints de prurigo nodulaire qui sont insuffisamment contrôlés par des traitements topiques prescrits ou lorsque ces traitements ne sont pas conseillés

acronym: LIBERTY-PN PRIME2

lead_sponsor: Sanofi-aventis Recherche & Développement


title:
A randomized, parallel-group, double-blind, placebo-controlled,
 multicenter Phase III trial to investigate the
 efficacy and safety of secukinumab 300 mg administered
 subcutaneously versus placebo, in combination with a
 glucocorticoid taper regimen, in patients with giant cell
 arteritis (GCA)

 Etude de phase III, multicentrique, randomisée, en double aveugle, à groupes parallèles, contrôlée par placebo, évaluant l’efficacité et la tolérance du sécukinumab 300 mg administré par voie sous-cutanée, en association à une diminution progressive de la dose de corticostéroïdes, chez des patients atteints d’artérite à cellules géantes (ACG)


title: A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis

acronym: HARBOR

lead_sponsor: Blueprint Medicines Corporation


title: AN OPEN-LABEL, NON-CONTROLLED, MULTICENTRE CLINICAL TRIAL OF INHALED MOLGRAMOSTIM IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS PATIENTS

acronym: IMPALA-EX

lead_sponsor: Savara ApS


title:
A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck

 Une étude pivot, en double aveugle, randomisée, contrôlée par placebo, multinationale du SGX942 (Dusquetide) pour le traitement de la mucite buccale chez des patients recevant une chimioradiothérapie concomitante pour traiter le carcinome à cellules squameuses de la tête et du cou

lead_sponsor: Soligenix UK Limited


title: A Phase 3 Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB024360) or Placebo in Participants with Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

acronym: Phase 3 Study of Pembro with/without Epacadostat in 1L Urothelial Carcinoma

lead_sponsor: Incyte Corporation


title: A Randomized Phase 3 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Alone or with Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer

acronym: Phase 3 Study of Pembrolizumab/Epacadostat/Chemotherapy in Metastatic NSCLC


title: A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TRK-750 in Colorectal Cancer Patients with Chemotherapy-induced Peripheral Neuropathy Following Oxaliplatin-containing Chemotherapy in the Adjuvant Setting

lead_sponsor: Toray Industries, Inc.


title: A double-blind randomized extension study to assess the long-term efficacy and safety of linzagolix in subjects with endometriosis-associated pain.

acronym: Edelweiss 3 extension

lead_sponsor: ObsEva S.A.


title: An Open-label, Randomized, Multi-center, Parallel Group, Two-arm Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir versus Standard of Care for Treatment of Adenovirus Infections in High-risk Pediatric Allogeneic Hematopoietic Cell Transplant Recipients

acronym: AdAPT: Adenovirus after Allogeneic Pediatric Transplantation

lead_sponsor: Chimerix, Inc


title: An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents with Homozygous Familial Hypercholesterolemia

lead_sponsor: Sanofi-Aventis Recherche & Développement


title: A Phase III, 3-Arm, Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of Diamyd® on the Progression of Diabetes in Patients Newly Diagnosed with Type 1 Diabetes Mellitus

lead_sponsor: Diamyd Therapeutics AB


title: A 24-month randomized, multicenter study, evaluating efficacy, safety, tolerability and pharmacokinetics of sotrastaurin (STN) combined with tacrolimus (TAC) vs a tacrolimus / mycophenolate mofetil (MMF) - based control regimen in de novo liver transplant recipients

lead_sponsor: Novartis Pharma Services AG


title: A MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF SUNITINIB MALATE VERSUS SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA

lead_sponsor: Pfizer Inc. - 235 East 42nd Street - New York - 10017


title: A 24-week, international, multi centre, randomised, double-blind, double-dummy, parallel group, phase IV clinical trial investigating changes in back pain in postmenopausal women with an osteoporosis related vertebral fracture(s) treated with either 100 µg PTH(1-84) daily or 70 mg alendronate weekly

acronym: RELIEF

lead_sponsor: Nycomed Danmark Aps


title: An Open Label, Randomized Phase I/IIa Trial Evaluating MK-0646 in Combination With Erlotinib (TARCEVA™) for Patients With Recurrent Non-Small Cell Lung Cancer"

lead_sponsor: Laboratoires Merck Sharp & Dohme - Chibret


title: A Phase 3, randomized, double-blind, placebo-controlled study of oral talactoferrin in addition to best supportive care in patients with non-small cell lung cancer who have failed two or more prior treatment regimens.

acronym: FORTIS-M

lead_sponsor: Agennix Incorporated


title: A multicenter, double-blind, randomized, parallel-group study to evaluate the safety, tolerability, and efficacy of once daily amlodipine/valsartan 5/80mg as compared to amlodipine/valsartan 5/40mg or to amlodipine 5mg once daily in elderly patients with essential hypertension not adequately controlled after four weeks on amlodipine 5mg once daily


title: A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1

lead_sponsor: Schering-Plough Research Institute, a Division of Schering Corporation


title: A randomized, placebo controlled, multicenter clinical study investigating efficacy of rituximab (MabThera/Rituxan) in the inhibition of joint structural damage assessed by magnetic resonance imaging in patients with rheumatoid arthritis and inadequate response to methotrexate - the SCORE study.

acronym: SCORE

lead_sponsor: F. Hoffman-La Roche Ltd.


title: A phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients with Metastatic Pancreatic Adenocarcinoma

lead_sponsor: Clovis Oncology Inc


title: GAP Grazax Asthma Prevention

acronym: GAP

lead_sponsor: ALK-Abelló A/S


title: A multi-center, randomized, open label, controlled study to compare the Sustained Virological Response during treatment with Neoral or tacrolimus in maintenance liver transplant recipients treated with pegylated interferon and ribavirin for recurrent Hepatitis C

acronym: SUSTAIN


title: A controlled, randomised, double-blind, double-dummy, parallel-group, phase III, multicenter study to evaluate efficacy and safety of the oral direct thrombin inhibitor AZD0837 compared to warfarin for the prevention of stroke and systemic embolic events (SEE) in patients with atrial fibrillation (ASSURE-AF)

acronym: ASSURE-AF

lead_sponsor: AstraZeneca AB


title: A Study of IPI-145 and Ofatumumab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07

lead_sponsor: Infinity Pharmaceuticals, Inc


title:
30-day, open-label, active-controlled, randomized study of the safety, efficacy and the
 pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in young
 children with various manifestations of venous thrombosis

acronym: EINSTEIN Junior Phase II-part B: oral rivaroxaban in young children with venous thrombosis

lead_sponsor: Bayer HealthCare AG


title: ENABLE 2 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE) Randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2b plus ribavirin)

acronym: ENABLE 2

lead_sponsor: GlaxoSmithKline Research & Development Ltd


title: A phase III, open-label, uncontrolled, multicentre, rollover study to assess safety and efficacy of LB03002 administered weekly in adults with growth hormone deficiency.

lead_sponsor: BioPartners GmbH


title: A Randomised Open Label, Multicentre Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE and Prednisone (VcR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in Patients with Newly Diagnosed Mantle Cell Lymphoma Who are Not Eligible for a Bone Marrow Transplant.

lead_sponsor: Janssen-Cilag International N.V.


title: A Phase III, randomised, parallel group, double-blind, double-dummy, active comparator -controlled, multi-center study to assess the efficacy and safety of PGL4001 (ulipristal) versus GnRH-agonist (leuprorelin 3.75mg) for pre-operative treatment of symptomatic uterine myomas.

acronym: PEARL II, PGL4001 versus GnRH-agonist in uterine myomas

lead_sponsor: PregLem S.A.


title: Efficacy and safety of inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia.

lead_sponsor: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)


title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Long Term Safety Study of MK-4305 in Patients with Primary Insomnia

lead_sponsor: Merck & Co., Inc.


title: Trial consisting of an 8-week double-blind placebo-controlled part to evaluate efficacy, safety, tolerability and pharmacokinetics of prucalopride in paediatric subjects with functional constipation, aged ≥6 months to <18 years, followed by a 16-week open-label comparator (PEG) controlled part, to document safety and tolerability up to 24 weeks

acronym: Not applicable

lead_sponsor: Shire-Movetis NV


title: A 24-week randomized placebo-controlled, double-blind multi-center clinical trial evaluating the efficacy and safety of oral QTI571 as an add-on therapy in the treatment of severe pulmonary arterial hypertension: Imatinib in Pulmonary arterial hypertension, a Randomized, Efficacy Study

acronym: IMPRES

lead_sponsor: Novartis Pharma AG


title: A 26-week treatment, multi center, randomized, double blind, double dummy, placebo controlled, parallel group study to assess the efficacy and safety of indacaterol (150 μg o.d.) in patients with chronic obstructive pulmonary disease, using salmeterol (50 μg b.i.d.) as an active control.

lead_sponsor: Novartis Pharma Services AG


title: AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects with Pulmonary Arterial Hypertension

acronym: AMBITION

lead_sponsor: GlaxoSmithKline Research & Development Limited


title: A prospective, multicenter, randomized, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib at 7.5 mg/kg/day to dacarbazine in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-kit

lead_sponsor: AB Science


title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric
 Subjects with Moderate to Severe Ulcerative Colitis.

lead_sponsor: Abbvie Deutschland GmbH & Co. KG


title:
Randomized Phase II study comparing single agent oral vinorelbine administered with two different schedules in patients with Advanced Non Small Cell Lung Cancer unfit for a platinum-based chemotherapy

 Étude randomisée de phase II comparant la vinorelbine orale en monothérapie administrée selon deux schémas différents, chez des patients atteints de cancer bronchique non à petites cellules avancé pour lesquels la chimiothérapie à base de platine n'est pas indiquée.

acronym: TEMPO LUNG 01

lead_sponsor: PIERRE FABRE MEDICAMENT


title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected with Respiratory Syncytial Virus

acronym: PLUM

lead_sponsor: Janssen-Cilag International NV


title: A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY ASSESSING THE EFFICACY AND SAFETY OF PF-06438179 AND INFLIXIMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO METHOTREXATE

lead_sponsor: Pfizer Inc.


title: An Open-labeled, Randomized, Parallel Group Trial of zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, versus Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma of the Head and Neck who have failed standard platinum-based chemotherapy.

lead_sponsor: Genmab A/S


title: A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid-Dependent Subjects.

lead_sponsor: Schering-Plough Research Institute


title: Efficacy and safety of oral budesonide-MMX™ (CB-01-02) 6 mg and 9 mg extended release tablets in patients with mild or moderate active ulcerative colitis.  A multicentre, randomised, double-blind, double-dummy, comparative study versus placebo with an additional reference arm evaluating entocort®EC

lead_sponsor: COSMO Technologies Ltd


title: A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combination tablet Ezetimibe/Simvastatin (10mg/20mg) compared to Rosuvastatin 10mg in patients with primary hypercholesterolemia and high cardiovascular risk and not adequately controlled with a  prior statin treatment. (IN-CROSS).

lead_sponsor: Laboratoires Merck Sharp & Dohme - Chibret


title: A 12-month open-label, randomized, multicenter, sequential cohort, dose finding study to evaluate the efficacy, safety and tolerability of oral AEB071 versus Neoral® in combination with Certican®, Simulect® and corticosteroids in de novo adult renal transplant recipients


title: A Study of Dose Optimization of Infliximab in the Treatment of Moderate to Severe Plaque Psoriasis.

acronym: DOSE

lead_sponsor: Schering Plough Research Institute, a Division of Schering Corporation


title: A 6-month, double-blind, randomized, placebo-controlled, parallel group outpatient trial, investigating the efficacy and safety of Org 50081 in adult patients with chronic primary insomnia.

acronym: AQUAMARINE

lead_sponsor: NV Organon


title: A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator’s Choice in Subjects with Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy

lead_sponsor: CytRx Corporation


title: An Open-Label, Long-Term Extension, Multi-center, Sequential Dose Titration Study to Assess Safety and Efficacy of Solifenacin Succinate Suspension in Pediatric Subjects with Overactive Bladder (OAB)

lead_sponsor: Astellas Pharma Europe B.V.


title:
A Multi-center, Double-blind, Randomized, Placebo Controlled Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption due to GI Immaturity in Preterm Infants.

 Étude multicentrique, en double aveugle, randomisée et contrôlée par placebo visant à évaluer l'efficacité et la tolérance du NTRA-2112 sur la malabsorption intestinale due à une immaturité du système digestif chez des nourrissons prématurés.

acronym: A Study to Assess the Efficacy and Safety of NTRA-2112 in Preterm Infants

lead_sponsor: Nutrinia


title:
A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY ASSESSING THE EFFICACY AND SAFETY OF PF-06410293 AND ADALIMUMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY
 TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN
 INADEQUATE RESPONSE TO METHOTREXATE


title: A double blind, within patient, placebo controlled trial to assess the efficacy of Juvista (avotermin) in conjunction with scar revision surgery for the improvement of disfiguring scars.

acronym: Juvista in scar revision surgery of disfiguring scars

lead_sponsor: Renovo Ltd


title: A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatment

lead_sponsor: AB SCIENCE


title:
Comparison of the Efficacy and Safety of Infliximab, as Monotherapy or in Combination With Azathioprine, Versus Azathioprine Monotherapy in Moderate to Severe Active Ulcerative Colitis (Part 1).
 Comparison of Maintenance Versus Intermittent Infliximab Treatment in Maintaining Remission:   A Follow-up of Efficacy and Safety (Part 2)

lead_sponsor: Schering-Plough Research Institute, a division of Schering Corporation


title: Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with Higher Copegus Doses in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater than or Equal to 85 kg

acronym: PROGRESS

lead_sponsor: F. Hoffmann-La Roche Ltd


title: A Multicenter, Randomized, Double-Blind, Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination Taken Orally for 8 Weeks in Adult Subjects with Essential Hypertension Who Are Inadequately Controlled on 16 mg Candesartan Cilexetil Monotherapy

lead_sponsor: Bayer HealthCare AG


title: A Phase II Open Label Study of MK-7009 Administered Concomitantly with Pegylated Interferon Alfa-2a and Ribavirin to Patients with Chronic Hepatitis C Infection After Participation in Other MK-7009 Clinical Trials

lead_sponsor: Merck & Co., Inc.


title: A Phase I/II Multi-centre Study of AZD8931 in Combination with Weekly Paclitaxel to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced Solid Tumours and in a Selected Population with Low HER2-expressing Locally Recurrent and/or Metastatic Breast Cancer (THYME)

acronym: THYME

lead_sponsor: AstraZeneca AB


title: A Randomised Phase III Study of Elacytarabine vs. Investigator’s Choice in Patients with Late Stage Acute Myeloid Leukaemia

lead_sponsor: Clavis Pharma


title: An open-label, multicentre, randomised phase II study of pazopanib in combination with pemetrexed in first-line treatment of subjects with predominantly non-squamous cell stage IIIBwet/IV non-small cell lung cancer

lead_sponsor: GlaxoSmithKline R&D Limited


title: A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control


title: An Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA™) as First line Treatment in Caucasian Patients, who have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)


title: "A Two-Part, Adaptive, Randomized Trial of Ridaforolimus in Combination with Dalotuzumab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Breast Cancer Patients"


title: A Randomized, Multicenter, Phase III Study Comparing the Combination of  Pazopanib and Lapatinib versus Lapatinib Monotherapy in Patients with ErbB2 over-expressing Inflammatory Breast Cancer

lead_sponsor: GlaxoSmithkline Research & Development Limited


title:
A phase III, randomised, open label, active-controlled study of an
 interferon-free regimen of BI 207127 in combination with Faldaprevir
 and Ribavirin compared to Telaprevir in combination with pegylated
 interferon-a and ribavirin in treatment-naive patients with chronic
 genotype 1b Hepatitis C Virus infection.

lead_sponsor: Boehringer Ingelheim France


title:
Assessment of Anatomical and Functional Outcomes in Patients Treated with Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion
 (VMT/sVMA)

lead_sponsor: Alcon Research, Ltd.


title: Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Monotherapy in Subjects with Signs and Symptoms of Osteoarthritis of the Hip or Knee

lead_sponsor: Janssen-Cilag International N.V.


title: A Parallel-Group, Double-Blind, Long Term Safety and Efficacy Trial of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD).

acronym: A Long Term Safety and Efficacy Trial of MK-8931 (SCH 900931) in Subjects with Prodromal AD (APECS)

lead_sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.


title: A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease

acronym: A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008)

lead_sponsor: NeuroSearch Sweden AB


title: A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphatemic Chronic Kidney Disease Patients Not on Dialysis

lead_sponsor: Genzyme Europe BV


title: A Randomized, Double-blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Two Doses of Tramadol Hydrochloride Orally Disintegrating Tablets in Male Subjects with Premature Ejaculation.

lead_sponsor: Biovail Laboratories International SRL, c/o Biovail Technologies Ltd


title: Phase III (Phase V Program), Open-Label, Randomized, Referred- Care-Controlled, Clinical Trial to Evaluate the Efficacy and Safety of MK-0217A/Alendronate Sodium 70 mg/Vitamin D3 5600 I.U. Combination Tablet on Vitamin D Inadequacy in the Treatment of Osteoporosis in Postmenopausal Women

lead_sponsor: Laboratoires Merck Sharp & Dohme - Chibret


title: A phase II randomized, controlled, open-labeled (dose-blinded) dose finding study of the safety and efficacy of I-040202 in the treatment of patients with acute open tibial shaft fractures

lead_sponsor: Kuros Biosurgery AG


title: Inhibitor Development in Previously Untreated Patients (PUPs) or Minimally Blood Component-Treated Patients (MBCTPs) when Exposed to plasma-derived von Willebrand Factor-Containing Factor VIII (VWF/FVIII) Concentrates and to Recombinant Factor VIII (rFVIII) Concentrates: An Independent, International, Multicentre, Prospective, Controlled, Randomised, Open Label, Clinical Trial.

acronym: SIPPET

lead_sponsor: FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI


title: A Multinational Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects with Moderate to Severe Crohn’s Disease

lead_sponsor: ChemoCentryx, Inc


title: A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of MK-7009 When Administered Concomitantly With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Infection


title: A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Once Daily Raltegravir (MK-0518) Versus Twice Daily Raltegravir, Each in Combination With TRUVADA™, in Treatment-Naïve HIV Infected Patients

lead_sponsor: Laboratoires Merck Sharp & Dhome-Chibret


title: An open-label, multicenter, expanded access study of imatinib mesylate in adult patients with GIST in adjuvant setting after R0-resection

lead_sponsor: Novartis Pharma GmbH


title: A pilot study to test the feasibility, safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lymphoblastic leukemia. A collaborative study of the Interfant network.

lead_sponsor: Princess Máxima Center for Pediatric Oncology


title: A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

acronym: Pembrolizumab plus epacadostat, and the EXTREME regimen as first line tre for R/M HNSCC

lead_sponsor: Incyte Corporation


title: A RANDOMIZED PHASE III TRIAL COMPARING CONVENTIONAL-DOSE CHEMOTHERAPY USING PACLITAXEL, IFOSFAMIDE, AND CISPLATIN (TIP) WITH HIGH-DOSE CHEMOTHERAPY USING MOBILIZING PACLITAXEL PLUS IFOSFAMIDE FOLLOWED BY HIGH-DOSE CARBOPLATIN AND ETOPOSIDE (TI-CE) AS FIRST SALVAGE TREATMENT IN RELAPSED OR REFRACTORY GERM CELL TUMORS

acronym: TIGER

lead_sponsor: European Organisation for Research and Treatment of Cancer


title: A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of a High Dose of Eteplirsen, Preceded by an Open-label Dose Escalation, in Patients with Duchenne Muscular Dystrophy With Deletion Mutations Amenable to Exon 51 Skipping

lead_sponsor: Sarepta Therapeutics, Inc.


title: A prospective randomised phase III study of androgen deprivation therapy with or without local  radiotherapy with or without abiraterone acetate and prednisone in patient with metastatic hormone-naïve prostate cancer.

lead_sponsor: UNICANCER


title: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children and Young Adults with Dravet Syndrome

lead_sponsor: Zogenix International Limited


title: A multicenter, randomized, double-blind study of dacarbazine with or without Genasense in chemotherapy naïve subjects with advanced melanoma and low LDH (The AGENDA Trial)

lead_sponsor: Genta Incorporated


title: Randomised controlled trial evaluating strategies to optimize disease activity control in RA patients treated with infliximab in clinical practice.

lead_sponsor: Integrated Therapeutics Group, Inc. - A subsidiary of Schering-Plough Corp.


title: A 12-month randomized, double-masked, controlled, multicenter, phase II study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with Lucentis™ versus Lucentis™ monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration

acronym: MONT BLANC

lead_sponsor: Novartis Pharma Services AG


title: A Phase II Study of MK-0457 in Patients With BCR-ABL T315I Mutant Chronic Myelogenous Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia


title: A Multicenter, Randomized, Double-Blind, Parallel Group, 12-Week Study to Evaluate the Efficacy and Safety of Extended-Release (ER) Niacin/Laropiprant Added to Statin Versus Doubling the Dose of Statin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia.

acronym: Extended Release Niacin/Laropiprant – Lipids


title: A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease


title: A Phase IIb/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose- Range Finding Clinical Trial of MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin

lead_sponsor: Laboratoires Merck Sharp & Dohme-Chibret


title: A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adults with Recent-Onset Type 1 Diabetes Mellitus

acronym: Protégé Encore

lead_sponsor: MacroGenics, Inc.


title: A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Peripheral Spondyloarthritis

lead_sponsor: Abbott GmbH & Co. KG


title: A European randomised Phase 3 study to assess the efficacy and safety of TOOKAD® Soluble for low risk localised prostate cancer compared to Active Surveillance

lead_sponsor: STEBA BIOTECH SA


title: Multinational, multicentre, prospective, open-label, uncontrolled clinical trial to assess the efficacy and safety of Autologous Cultivated Limbal Stem Cells Transplantation (ACLSCT) for restoration of corneal epithelium in patients with limbal stem cell deficiency due to ocular burns

acronym: HOLOCORE

lead_sponsor: Chiesi Farmaceutici S.p.A.


title:
Safety and Efficacy of Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for the Treatment of Acute Intermediate-Risk Pulmonary Embolism.

 Safety and efficacy of low molecular weight heparin for at least 72 hours followed by Dabigatran for the treatment of acute intermediate-risk pulmonary embolism PEITHO-2

lead_sponsor: JOHANNES GUTENBERG UNIVERSITY


title: A phase III, double-blind, randomized, placebo-controlled, parallel-group, multicenter study to assess efficacy and safety of LB03002 administered weekly in adults with growth hormone deficiency.

lead_sponsor: BioPartners GmbH


title: A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Study  the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) to Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Therapy (Alone or In Combination with Metformin)


title: A European Phase III, Multicentre, Double-blind, Randomised, Placebo-Controlled Monotherapy Study of Milnacipran for the Treatment of the Fibromyalgia Syndrome.

acronym: FMS Europe

lead_sponsor: Pierre Fabre Medicament


title: Double-blind, randomized, placebo-controlled, dose-finding, parallel-group study to assess the hemodynamic effects, clinical efficacy, tolerability and safety of Aviptadil (Vasoactive Intestinal Peptide) after single and repeated inhalation in patients with pulmonary arterial hypertension.

lead_sponsor: MondoGEN AG


title: A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination with Pemetrexed (Alimta®) versus Pemetrexed alone in Patients with Locally-Advanced or Metastatic (stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC) after Failure of 1st Line Anti-cancer Therapy

lead_sponsor: AstraZeneca AB


title: Etude prospective, randomisée, en double aveugle versus placebo, internationale, groupe parallèle, évaluant l'efficacité et la sécurité d'un bolus I.V de tenecteplase en comparaison avec un traitement standard chez des patients normotensifs ayant une embolie pulmonaire aigue.

acronym: PEITHO

lead_sponsor: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)


title: A Phase III, Multicenter, Ramdomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Intramuscular Peramivir in Subjects with Uncomplicated Acute Influenza

acronym: The IMPROVE 2 Study

lead_sponsor: BioCryst Pharmaceuticals


title: A double blind, randomized, placebo-controlled, parallel group, multicenter Phase 3 pivotal study to assess the safety and efficacy of 1mg/kg/day intravenous DP-b99 over 4 consecutive days versus placebo when initiated within nine hours of acute ischemic stroke onset

acronym: MACSI

lead_sponsor: D-Pharm Ltd.


title: A MULTICENTER, RANDOMIZED, DOUBLE-MASKED, 3 PARALLEL ARMS, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF NOVA22007 1MG/ML (CICLOSPORIN/CYCLOSPORINE) EYE DROPS, EMULSION ADMINISTERED IN PAEDIATRIC PATIENTS WITH ACTIVE SEVERE VERNAL KERATOCONJUNCTIVITIS WITH SEVERE KERATITIS

lead_sponsor: Novagali Pharma S.A.S.


title: A dose-finding phase Ib study followed by a randomized, double-blind phase II study of carboplatin and paclitaxel with or without buparlisib in patients with previously untreated metastatic non-small cell lung cancer (NSCLC) of squamous histology


title: A Multicenter, Randomized, Controlled, Two-Arm, Phase III Study to Evaluate the Safety and Efficacy of MK-3475 Compared to Ipilimumab in Patients with Advanced Melanoma

lead_sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as the SPONSOR or Merck)


title: A phase II, multicenter, randomized, double-masked, 4 parallel arms, controlled 6-month trial designed to evaluate the safety and efficacy of PAD ciclosporin (CsA 0.06% and 0.03%) ophthalmic dispersion administered once daily in combination with lubricant therapy and a 3-month post-treatment safety follow-up in moderate to severe dry eye patients

lead_sponsor: DRUG DELIVERY SOLUTIONS ApS (PART OF MC2 BIOTEK GROUP)


title:
A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents with Atypical Hemolytic Uremic Syndrome (aHUS)

 Étude de phase III, en ouvert, multicentrique, évaluant l’ALXN1210 chez des enfants et des adolescents atteints du syndrome hémolytique et urémique atypique (SHUa)

lead_sponsor: Alexion Pharmaceuticals Incorporated


title:
PHASE 1B/PHASE 3 MULTICENTER STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION REGIMENS THAT INCLUDE AN IMMUNE AGONIST, EPIGENETIC MODULATOR, CD20 ANTAGONIST AND/OR CONVENTIONAL CHEMOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

 ÉTUDE DE PHASE IB/III MULTICENTRIQUE PORTANT SUR L’AVÉLUMAB (MSB0010718C) DANS DES ASSOCIATIONS THÉRAPEUTIQUES INCLUANT UN AGONISTE IMMUNITAIRE, UN MODULATEUR ÉPIGÉNÉTIQUE, UN ANTAGONISTE DE CD20 ET/OU UNE CHIMIOTHÉRAPIE CLASSIQUE CHEZ DES PATIENTS ATTEINTS DE LYMPHOME DIFFUS À GRANDES CELLULES B (LDGCB) RÉCIDIVANT OU RÉFRACTAIRE

acronym: JAVELIN DLBCL

lead_sponsor: Pfizer Inc, 235 East 42nd Street, New York, NY 10017


title: Effects of Plasma Exchange with Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects with "Acute-On-Chronic Liver Failure" (ACLF) at High Risk of Hospital Mortality

acronym: APACHE

lead_sponsor: Instituto Grifols S.A.


title: A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT®) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORS

lead_sponsor: Pfizer Inc.


title: A multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to sitagliptin and placebo in patients with type 2 diabetes mellitus inadequately controlled with metformin.

lead_sponsor: F.Hoffmann-La Roche Ltd


title: A randomized, multi center, parallel group, double-blind, placebo and formoterol controlled 14 day dose ranging trial 4 doses of indacaterol delivered via  Twisthaler®, in patients with COPD.

lead_sponsor: Novartis Pharma Services AG


title: Phase II randomised, double blind, multicentre study to assess the efficacy of AZD2281 in the treatment of patients with platinum sensitive serous ovarian cancer following treatment with two or more platinum containing regimens


title: A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the Acute Treatment of Migraine With or Without Aura

lead_sponsor: Laboratoires Merck Sharp & Dohme - Chibret


title: A randomized, multicenter phase II study to explore whether biomarkers correlate with treatment outcome in chemo-naive patients with advanced or recurrent non-squamous non-small cell lung cancer, who receive treatment with bevacizumab (at a dose of either 7.5 mg/kg or 15 mg/kg) in addition to carboplatin based chemotherapy (gemcitabine or paclitaxel)

lead_sponsor: F. Hoffmann La-Roche Ltd


title: Two-arm, randomized, open-label, phase IIIb study investigating the safety of a 3 hour i.p. infusion of catumaxomab with and without prednisolone premedication in patients with malignant ascites due to epithelial cancer

acronym: CASIMAS

lead_sponsor: Fresenius Biotech GmbH


title: A Phase III, Multicentre, Randomised, Placebo-Controlled, Double Blind Study of the Incidence of Recurring Pulmonary Exacerbations in Cystic Fibrosis Patients using Two Different Doses of Inhaled Nacystelyn®

lead_sponsor: Laboratoires SMB S.A.


title: A PROSPECTIVE, RANDOMIZED TRIAL COMPARING THE SAFETY, TOLERABILITY, AND EFFICACY OF VORICONAZOLE AND ANIDULAFUNGIN IN COMBINATION TO THAT OF VORICONAZOLE ALONE WHEN USED FOR PRIMARY THERAPY OF INVASIVE ASPERGILLOSIS IN PEDIATRIC SUBJECTS AGED 2 TO 17 YEARS

lead_sponsor: Pfizer Inc. 235 East 42nd Street, New York, NY 10017


title: An open-label, multi-center, expanded access study of RAD001 in patients with subependymal giant cell astrocytomas (SEGA) associated with tuberous sclerosis complex (TSC). The EFFECTS STUDY: Everolimus For Fast Expanded aCcess in TSC SEGA

acronym: EFFECTS STUDY


title: A Phase 2, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma

lead_sponsor: MedImmune, LLC


title: A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma

lead_sponsor: Incyte Corporation


title: A prospective, multicenter, randomized, double-blind, placebo-controlled, 2-parallel group, phase 3 study to compare efficacy and safety of masitinib 9 mg/kg/day in combination with bortezomib and dexamethazone to placebo in combination with bortezomib and dexamethazone in the treatment of patients with relapsing multiple myeloma who received one previous therapy

lead_sponsor: AB Science


title:
A Non-Controlled, Open-Label, Multicenter, Study of Immune Tolerance Induction Performed with rFVIIIFc within a Timeframe of 60 Weeks in Severe Haemophilia A Patients with Inhibitors who have Failed Previous Immune Tolerance Induction Therapies

 Étude multicentrique, non contrôlée, en ouvert, évaluant l'immunotolérance induite par rFVIIIFc pendant une période de 60 semaines chez des patients atteints d'hémophilie A sévère sous inhibiteurs, n'ayant pas répondu à des traitements antérieurs d'immunotolérance

lead_sponsor: Swedish Orphan Biovitrum AB (publ)


title:
A phase III trial evaluating the efficacy and safety of the house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet in children and adolescents (5-17 years) with HDM allergic asthma

 Étude de Phase III évaluant l’efficacité et la bonne tolérance du comprimé d'immunothérapie sublinguale aux acariens (comprimé HDM-SLIT) chez des enfants et des adolescents âgés de 5 à 17 ans présentant un asthme allergique aux acariens de la poussière de maison.

lead_sponsor: ALK-Abelló A/S


title:
A randomized, double blind, multicenter extension to CZPL389A2203 dose-ranging study to assess the short-term and long-term safety and efficacy of oral ZPL389 with concomitant or intermittent use of TCS and/or TCI in adult patients with atopic dermatitis (ZEST Extension)

 Protocole d’extension de l’étude CZPL389A2203, dose-réponse, multicentrique, randomisée, en double aveugle, évaluant à court terme et à long terme la tolérance et l’efficacité de ZPL389 par voie orale avec une utilisation concomitante ou intermittente de dermocorticoïdes et/ou d’inhibiteurs de la calcineurine topiques chez des patients adultes atteints de dermatite atopique (Extension de l’étude ZEST)

acronym: ZEST Extension

lead_sponsor: Novartis Pharma AG


title: A prospective, multicenter, randomised, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib to sunitinib in patients with gastrointestinal stromal tumor resistant to imatinib


title:
A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients with metastatic colorectal cancer

 Etude de phase 3, prospective, multicentrique, randomisée, en double aveugle, contrôlée, avec 2 groupes parallèles, visant à comparer l’efficacité et la tolérance de masitinib en association avec FOLFIRI (irinotecan, 5-fluorouracil et acide folinique) versus placebo en association avec FOLFIRI, chez des patients atteint d’un cancer colorectal métastatique en 2ème ligne de traitement


title: A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor.

acronym: The APOLLO Study

lead_sponsor: European Myeloma Network (EMN)


title: A Clinical Study to Evaluate the Safety and Effectiveness of NOVOCART® 3D plus Compared to Microfracture in the Treatment of Articular Cartilage Defects of the Knee.

lead_sponsor: TETEC – Tissue Engineering Technologies – AG


title:
A multicenter, randomized, double-blind, placebo- controlled phase 2b dose-finding study to investigate the efficacy, safety and tolerability of LOU064 in adult chronic spontaneous urticaria patients inadequately controlled by H1-antihistamines

 Etude de phase IIb, multicentrique, randomisée, en double aveugle, contrôlée contre placebo, visant à déterminer la dose optimale de LOU064 et à évaluer l’efficacité, la sécurité d’emploi et la tolerance de ce traitement chez des patients adultes  souffrant d’urticaire chronique spontanée (UCS) non contrôlée par un traitement antihistaminique anti-H1


title: Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS: open label extension for patients completing study 3119002

acronym: REFALS-ES

lead_sponsor: Orion Corporation


title: A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients with AdvanCed Gastrointestinal Stromal TUmorS who have Received Treatment with Prior Anticancer Therapies

acronym: INVICTUS

lead_sponsor: Deciphera Pharmaceuticals, LLC


title:
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 AND DUPILUMAB IN COMPARISON WITH PLACEBO IN ADULT SUBJECTS ON BACKGROUND TOPICAL THERAPY, WITH MODERATE TO SEVERE ATOPIC DERMATITIS

 ÉTUDE DE PHASE III RANDOMISEE, MULTICENTRIQUE, EN DOUBLE AVEUGLE, A DOUBLE PLACEBO, CONTROLEE PAR PLACEBO, A GROUPES PARALLELES, VISANT A EXAMINER L’EFFICACITE ET LA SECURITE DU PF 04965842 ET DU DUPILUMAB PAR RAPPORT A UN PLACEBO CHEZ DES PATIENTS ADULTES ATTEINTS DE DERMATITE ATOPIQUE MODEREE A SEVERE, SOUS TRAITEMENT TOPIQUE DE FOND

lead_sponsor: Pfizer Inc.


title: A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Of Pracinostat In Combination With Azacitidine In Patients ≥18 Years With Newly Diagnosed Acute Myeloid Leukemia Unfit For Standard Induction Chemotherapy

lead_sponsor: Helsinn Healthcare SA


title: A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open-label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome

lead_sponsor: Cortendo AB


title: A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotrophic Lateral Sclerosis

lead_sponsor: Orphazyme A/S


title: A Multicenter, Randomized, Double blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects with Basal Cell Nevus Syndrome

acronym: PATIDEGIB study

lead_sponsor: PellePharm, Inc.


title: IDH mutated 1p/19q intact lower grade glioma following resection: Wait Or Treat? IWOT – A phase III study

acronym: IWOT

lead_sponsor: European Organisation for Research and Treatment of Cancer


title: A phase I/II study of Bosutinib in pediatric patients with Chronic Myeloid Leukemia who are resistant or intolerant to at least one prior Tyrosine Kinase Inhibitor therapy, ITCC-054/AAML1621

acronym: Bosutinib in pediatric CML

lead_sponsor: Erasmus MC


title:
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2)

 Étude d'extension en ouvert évaluant l'efficacité et la sécurité à long terme de l'A4250 chez des enfants atteints de cholestase intrahépatique progressive familiale de types 1 et 2 (PEDFIC 2)

lead_sponsor: Albireo AB


title: A Non-Randomized, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of ReFacto AF in Previously Treated Pediatric Subjects Less Than Twelve Years of Age With Severe Hemophilia A (FVIII:C <1%)

lead_sponsor: Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company


title: A Randomized, Multi-center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma

acronym: CheckMate 459

lead_sponsor: Bristol-Myers Squibb International Corporation


title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

lead_sponsor: Acerta Pharma BV


title: An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued pasireotide treatment

lead_sponsor: Novartis Pharma Services AG


title: A Randomised, Placebo Controlled, Double-Blinded Comparative Study Evaluating the Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Translplant Patients Converted to Sirolimus

lead_sponsor: Wyeth Pharmaceuticals


title: A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study To Evaluate The Efficacy and Safety of Two Doses of Ocrelizumab in Subjects With WHO or ISN Class III or IV Nephritis Due To Systemic Lupus Erythematosus

lead_sponsor: F. Hoffmann-La Roche Ltd


title: A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor.

lead_sponsor: Incyte Corporation


title: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene

lead_sponsor: Alector Inc.


title:
An open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat (LCI699) study and are judged by the investigator to benefit from continued treatment with osilodrostat

 Etude multicentrique, en ouvert et de poursuite du traitement afin d’évaluer la tolérance à long terme chez des patients atteints du syndrome de Cushing endogène ayant terminé une précédente étude Novartis portant sur l’osilodrostat (LCI699) et continuant à bénéficier du traitement par osilodrostat selon leur médecin-investigateur

lead_sponsor: Novartis Pharma AG


title:
A Randomized, Double-blind Study To Evaluate the Efficacy
 and Safety of Cabozantinib (XL184) at 60 mg/Day Compared
 to 140 mg/Day in Progressive, Metastatic Medullary Thyroid
 Cancer Patients

acronym: EXAMINER

lead_sponsor: Exelixis, Inc.


title:
A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma

 Étude randomisée de phase III visant à comparer l’association IMO-2125 et ipilimumab versus ipilimumab seul chez des sujets présentant un mélanome réfractaire aux anticorps anti-PD-1

lead_sponsor: Idera Pharmaceuticals, Inc.


title: An Open-Label, Long-Term Safety Study Including a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period of TEV-50717 (deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents

acronym: ARTISTS

lead_sponsor: Teva Branded Pharmaceutical Products R&D, Inc.


title:
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) versus Pegylated Liposomal Doxorubicin or Topotecan in Patients with Platinum-resistant Ovarian Cancer (CORAIL Trial)

 Étude clinique de phase III, randomisée, comparant la lurbinectédine (PM01183) à la doxorubicine liposomale pégylée ou au topotécan chez des patientes présentant un cancer de l’ovaire résistant au platine (Etude CORAIL)

acronym:
CORAIL Trial

 Etude CORAIL

lead_sponsor: Pharma Mar S.A., Sociedad Unipersonal


title:
Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end point (PROBE) study- the CARAVAGGIO study.

 APIXABAN POUR LE TRAITEMENT DE LA THROMBOEMBOLIE VEINEUSE CHEZ LES PATIENTS CANCÉREUX : UNE ÉTUDE PROSPECTIVE ALÉATOIRE AVEC CRITÈRE À L'INSU (PROBE) - ÉTUDE CARAVAGGIO

acronym:
CARAVAGGIO

 CARAVAGGIO

lead_sponsor: FONDAZIONE FADOI


title: A Long-term Follow-up of Study 64041575RSV2004 to Evaluate the Impact of Lumicitabine (JNJ-64041575) on the Incidence of Asthma and/or Wheezing in Infants and Children with a History of Respiratory Syncytial Virus Infection

acronym: PLUM Follow-up

lead_sponsor: Janssen-Cilag International NV


title: A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients with Duchenne Muscular Dystrophy (DMD) who completed the SIDEROS study

acronym: SIDEROS-E

lead_sponsor: Santhera Pharmaceuticals (Switzerland) Limited


title:
An Open-Label, Multi-Center, Global Study to Evaluate Long Term Safety and Efficacy in Patients Who are Receiving or Who Previously Received Durvalumab in Other Protocols (WAVE)

 Étude ouverte, multicentrique, internationale, visant à évaluer l'innocuité et l’efficacité à long terme du durvalumab chez des patients qui reçoivent ou qui ont déjà reçu du durvalumab dans d’autres protocoles (WAVE)

acronym: WAVE

lead_sponsor: AstraZeneca AB


title: A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy (BOLD)

lead_sponsor: Albireo AB


title:
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared with PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected with Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)ide Therapy (D-LIVR)

 Étude randomisée de phase III, avec un plan matriciel et partiellement en double aveugle, visant à évaluer l’efficacité et la sécurité d’emploi de 50 mg de lonafarnib et 100 mg de ritonavir administrés deux fois par jour pendant 48 semaines, associés ou non à 180 µg de peginterféron alfa-2a, en comparaison avec une monothérapie de peginterféron alfa-2a et un traitement par placebo chez des patients présentant une infection chronique par le virus de l’hépatite D et recevant un traitement d’entretien par nucléoside(tide) anti-VHB (Virus de l’hépatite B) (D-LIVR)

acronym: D-LIVR

lead_sponsor: Eiger BioPharmaceuticals, Inc.


title: MRX-503: An Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis (PFIC)

lead_sponsor: Mirum Pharmaceuticals Inc.


title:
Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)

 Étude de phase 3, randomisée, en double insu, évaluant un traitement par tucatinib ou placebo en association à l’ado-trastuzumab emtansine (T-DM1) chez des patients atteints d’un cancer du sein HER 2 positif métastatique ou localement avancé non résécable (HER2CLIMB-02)

lead_sponsor: Seattle Genetics, Inc.


title: A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination with Pembrolizumab and 5FU-Platinum Chemotherapy versus Placebo in Combination with Pembrolizumab plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

lead_sponsor: GlaxoSmithKline Research & Development Ltd


title: An Open-Label Extension (OLE) Study to Evaluate the Efficacy and Safety of Nefecon Treatment in Patients With IgA Nephropathy Who Have Completed Study Nef-301

lead_sponsor: Calliditas Therapeutics AB


title: A Rollover Protocol to allow continued access to Tivozanib (AV-951) for subjects enrolled in other Tivozanib Protocols

lead_sponsor: AVEO Pharmaceuticals, Inc.


title:
A Phase 3, Randomized, Double-blind Study of Duvelisib Administered in Combination with Rituximab and Bendamustine vs Placebo Administered in Combination with Rituximab and Bendamustine in Subjects with Previously-Treated Indolent Non-Hodgkin Lymphoma

 Etude de phase 3, randomisée, en double aveugle comparant le duvelisib administré en association avec du rituximab et de la bendamustine contre placebo administré en association avec du rituximab et de la bendamustine chez des patients atteints de lymphome non hodgkinien indolent antérieurement traité

lead_sponsor: Infinity Pharmaceuticals, Inc.


title: Open-label, individual dose titration study to evaluate safety, tolerability and pharmacokinetics of riociguat in children from 6 to less than 18 years of age with pulmonary arterial hypertension (PAH)

acronym: PATENT-CHILD

lead_sponsor: Bayer Healthcare AG


title:
A PHASE 3B RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY,
 ACTIVE CONTROLLED MULTI-CENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS

 ÉTUDE MULTICENTRIQUE DE PHASE 3B, RANDOMISÉE, EN DOUBLE AVEUGLE, À DOUBLE PLACEBO, AVEC TRAITEMENT DE RÉFÉRENCE, VISANT À ÉVALUER L’EFFICACITÉ ET LA SÉCURITÉ D’EMPLOI DE L’ABROCITINIB COMPARÉ AU DUPILUMAB CHEZ DES PARTICIPANTS ADULTES ATTEINTS DE DERMATITE ATOPIQUE MODÉRÉE À SÉVÈRE RECEVANT UN TRAITEMENT TOPIQUE DE FOND

lead_sponsor: Pfizer Inc.


title: A multicentre study for the long-term follow-up of HLH patients who received treatment with NI-0501, an anti-interferon gamma monoclonal antibody

lead_sponsor: Novimmune SA


title: A Phase 3, international, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of glepaglutide in patients with short bowel syndrome (SBS)

acronym: Ease SBS 1 - Efficacy And Safety Evaluation of Glepaglutide in treatment of SBS

lead_sponsor: Zealand Pharma A/S


title: A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients with Short Bowel Syndrome (SBS)

acronym: EaseSBS 2 - Efficacy And Safety Evaluation of Glepaglutide in treatment of SBS


title: A phase 3, randomized, double-blind trial of nivolumab in combination with intravesical BCG versus standard of care BCG alone in participants with high-risk non-muscle invasive bladder cancer that is persistent or recurrent after treatment with BCG

lead_sponsor: Bristol-Myers Squibb International Corporation


title: Efficacy and tolerance of the emollient cream V0034 CR in the symptomatic treatment of ichthyosis in children. International, multicentric, randomised, controlled, double blind study, in parallel groups V0034 CR versus vehicle.

lead_sponsor: PIERRE FABRE MEDICAMENT


title: A randomized, double blind, placebo controlled, parallel group, multiple dose, induction study to evaluate the safety, tolerability and optimal dose of ABX464 compared with placebo in patients with moderate to severe ulcerative colitis who have inadequate response, loss of response, or intolerance with at least one of the following agents: immunosuppressant treatment (i.e. azathioprine, 6-mercaptopurine, methotrexate), tumor necrosis factor alpha [TNF-α] inhibitors, vedolizumab, JAK inhibitors and/or corticosteroid treatment.

lead_sponsor: ABIVAX


title: A double-blind, randomized, placebo-controlled, parallel group study of rimonabant 20 mg daily for the treatment of non-diabetic patients with nonalcoholic steatohepatitis (NASH)

lead_sponsor: sanofi-aventis Recherche & D2veloppement

status: Suspended by CA


title: BOTOX® in the Treatment of Urinary Incontinence Due to Overactive Bladder in Patients 12 to 17 Years of Age

lead_sponsor: Allergan Limited


title: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane

acronym: CONTESSA

lead_sponsor: Odonate Therapeutics, LLC


title: A phase 3, open-label, randomized, multicenter, 12 months, efficacy and safety study of weekly mod-4023 compared to daily genotropin® therapy in pre-pubertal children with growth hormone deficiency

lead_sponsor: OPKO Biologics Ltd.


title: A 52 week, randomised, double blind, multinational, multicentre, 4-arm parallel group trial to assess the efficacy and safety of 3 doses of CHF 6532 (10, 25 or 50 mg BID) compared to placebo on top of standard of care in subjects with uncontrolled severe eosinophilic asthma.

lead_sponsor: Chiesi Farmaceutici S.p.A.


title: A Phase 2 Study to Evaluate Dose and Duration of Treatment of Drotrecogin Alfa (Activated) Using Serial Measurements of Protein C in Patients with Severe Sepsis and Multiple Organ Dysfunction

acronym: RESPOND

lead_sponsor: Eli Lilly & Company Limited


title: A Prospective Randomized Open-label 6-Month Head-To-Head Trial to Compare Metabolic Effects of Paliperidone ER and Olanzapine in Subjects With Schizophrenia

lead_sponsor: Janssen-Cilag International NV,Turnhoutseweg 30, 2340 Beerse, Belgium


title: A 24-week, multicenter, multinational, randomized, double-blind, triple-dummy, 3-arm parallel group study comparing the efficacy and safety of CHF 1535 200/6 (beclomethasone dipropionate 200 μg plus formoterol 6 μg/actuation), 2 puffs b.i.d., versus beclomethasone diproprionate HFA (250 μg/actuation), 4 puffs b.i.d., versus Seretide® 500/50 (fluticasone 500 μg plus salmeterol 50 μg/actuation), 1 inhalation b.i.d., in patients with severe asthma

lead_sponsor: CHIESI FARMACEUTICI S.p.A.


title: ENABLE 1 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE) Randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2a plus ribavirin)

acronym: ENABLE 1

lead_sponsor: GlaxoSmithKline Research & Development Ltd


title: A phase III study to compare SonoVue®  enhanced myocardial echocardiography (MCE) to single photon emission computerized tomography (ECG-GATED SPECT), at rest and at peak of low-dose Dipyridamole stress test, in the assessment of significant coronary artery disease (CAD) in patients with suspect or known CAD using Coronary Angiography as Gold Standard

acronym: SonoVue MCE vs SPECT

lead_sponsor: Bracco Imaging S.p.A.


title: A randomised, double-blind, placebo- and active comparator-controlled, five parallel groups study to investigate the efficacy and safety of BI 44370 TA (50 mg, 200 mg, and 400 mg) administered orally once during an acute migraine attack of moderate or severe intensity

lead_sponsor: Boehringer Ingelheim France


title: Safety and Efficacy of Exenatide Once Weekly Injection versus Metformin, Dipeptidyl  Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients with Type 2 Diabetes

acronym: GWCH

lead_sponsor: Eli Lilly and Company


title: A randomized double blind phase III trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy.

acronym: PALETTE

lead_sponsor: GlaxoSmithKline Research & Development Limited


title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

acronym: ARTEMIS

lead_sponsor: Gilead Sciences Incorporated


title: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension

lead_sponsor: United Therapeutics Corporation


title:
A SAFETY AND EFFICACY TRIAL EVALUATING THE USE OF APIXABAN FOR THE EXTENDED TREATMENT OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM
 Revised Protocol 01 (version 4.0 dated 21-Apr-08), incorporating Amendment 02 (version 1.0 dated 21-Apr-08)

lead_sponsor: Bristol-Myers Squibb International Corporation


title: A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy

lead_sponsor: Cougar Biotechnology, Inc


title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO)

lead_sponsor: Alexion Pharmaceuticals, Inc.


title:
A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High Risk RetroPeritoneal Sarcoma

 Étude randomisée de phase III comparant une chimiothérapie néoadjuvante suivie d’une chirurgie et une chirurgie seule chez des patients atteints d’un sarcome rétropéritonéal à risque élevé

acronym: STRASS 2

lead_sponsor: European Organisation for Research and Treatment of Cancer


title: Interventional, randomized, double-blind, parallel-group, placebo-controlled delayed-start study to evaluate the efficacy and safety of eptinezumab in patients with episodic Cluster Headache

lead_sponsor: H. Lundbeck A/S


title: Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer

acronym: CILAB

lead_sponsor: Sanofi-Aventis Recherche et Développement


title: A Phase III, Multicentre, Open Label, Flexible dose, Long term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis with Hyperphosphataemia (incorporating a Comparison with Sevelamer).

lead_sponsor: Mitsubishi Pharma Corporation


title: A phase IV, open-label, multi-centre trial evaluating the conversion from standard phosphate binder therapy to Fosrenol in chronic kidney disease stage 5 patients on haemodialysis

lead_sponsor: Shire Pharmaceutical Development Ltd


title: A double-blind, multicenter, international randomised study to assess the effects of 6 months or 12 months  administration of 2g per day of strontium ranelate versus alendronate 70mg per week on bone remodelling and bone safety assessed by histomorphometry in women with postmenopausal osteoporosis

lead_sponsor: Institut de Recherches Internationales Servier


title: A Multi-center, Randomized, Parallel Group, Double-blind, Placebo Controlled Estimation Study to Assess the Efficacy and Safety of Modified Release UK-369,003 in the Treatment of Men with Storage Lower Urinary Tract Symptoms (LUTS) With and Without Erectile Dysfunction (ED)

acronym: not applicable

lead_sponsor: Pfizer Ltd


title: A 16-Week International, Multicenter, Double-Blind,  Randomized, Placebo Controlled  Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects with Pulmonary Arterial Hypertension

acronym: FREEDOM-C


title: A PHASE 2 RANDOMIZED, MULTICENTER, ACTIVE COMPARATOR-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF COADMINISTRATION OF CP-690,550 AND MYCOPHENOLATE MOFETIL / MYCOPHENOLATE SODIUM IN DE NOVO KIDNEY ALLOGRAFT RECIPIENTS

lead_sponsor: Pfizer Inc. 235 East 42nd Street, New York, NY10017


title: A phase III multi-center, open-label, randomized study of nilotinib versus imatinib in adult patients with  Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML - CP) who have suboptimal cytogenetic response (CyR) on imatinib.

lead_sponsor: Novartis Pharma Services


title: Open-Label Extension Study to Assess the Safety of a Fixed Dose of Subcutaneous Methylnaltrexone in Subjects With Advanced Illness and Opioid-Induced Constipation

lead_sponsor: Wyeth Research Division of Wyeth Pharmaceuticals Inc., Global Medical Affairs


title: A RANDOMISED, DOUBLE-BLIND, ADD-ON STUDY OF HYDROCHLOROTHIAZIDE IN SUBJECTS WITH MODERATE TO SEVERE HYPERTENSION NOT ACHIEVING TARGET BLOOD PRESSURE ON OLMESARTAN MEDOXOMIL/AMLODIPINE FIXED DOSE COMBINATION 40/10 MG ALONE

lead_sponsor: DAIICHI SANKYO EUROPE GmbH


title: An evaluation of the Ocular Surface Health in Subjects Using DuoTrav APS Eye Drops Solution Versus XALACOM® EYE Drops Solution

lead_sponsor: Alcon Research, Ltd.


title: An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults with Partial-Onset Seizures.

lead_sponsor: GlaxoSmithKline Research & Development Limited


title: A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III, Efficacy and Safety Study of TC-5214 (S mecamylamine) in Flexible Doses as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy

lead_sponsor: AstraZeneca AB


title: Open-label safety and tolerability of dabigatran etexilate mesilate given for 3 days at the end of standard anticoagulant therapy in successive groups of children aged 2 years to less than 12 years, and 1 year to less than 2 years.

lead_sponsor: Boehringer Ingelheim France


title:
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281)

 Etude de Phase III randomisée, en double-aveugle, et contrôlée par placebo évaluant l'efficacité et la tolérance  de capivasertib + abiratérone versus placebo + abiratérone chez des patients atteints d’un cancer métastatique de la prostate hormono-sensible (mHSPC) nouvellement diagnostiqué, caractérisé par un déficit en PTEN (CAPItello-281)


title: A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects with Schizophrenia

lead_sponsor: Janssen-Cilag International N.V.


title: Multicenter, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of tezosentan in patients with pre-operative pulmonary hypertension, due to left heart disease, undergoing cardiac surgery

lead_sponsor: Actelion Pharmaceuticals Ltd